Chart: Lilly Gilds Zyprexa Study, Violates FD&C Act With Sales Rep Chats
Lilly's settlement with the government on charges of off-label promotion of Zyprexa resulted in a record-setting fine (see following story). Documents from the U.S. v. Lilly case illustrate the dramatic impact shifting standards can have on company dissemination practices. Although one study suggested Zyprexa was effective in treating Alzheimer's disease, other studies confirmed the antipsychotic was no better than placebo. Because it could not substantiate Zyprexa's efficacy in AD, Lilly abandoned efforts to secure regulatory approval for Alzheimer's psychosis in November 2001. The practice described below violates a number of recommendations in the new reprint guidance, including the lack of comprehensive bibliography and lack of studies showing evidence to the contrary (see preceding story). Below is an excerpt from the U.S. Attorney's take on how Lilly crossed the line.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth